CLINICAL TRIALS PROFILE FOR EVICEL FIBRIN SEALANT (HUMAN)

All Clinical Trials for EVICEL FIBRIN SEALANT (HUMAN)

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01226914 ↗	A Trial Comparing Wound Drainage and Post-operative Complications With and Without the Use of EVICEL™ Fibrin Sealant in Thyroidectomy	Completed	Ethicon, Inc.	N/A	2010-06-01	Primary Objectives - To compare the amount of post-operative wound drainage between the group of patients in which EVICEL™ spray is utilized (Arm A), and the group of patients in which an EVICEL™ placebo is utilized (Arm B). - To compare the length of time to drain removal between Arm A and Arm B. Secondary objectives - To compare the incident or rates of seroma, hematoma, and post-operative edema between the two groups. - To compare the reported pain experienced in each group at selected time points using a standard numerical rating scale (NRS). - To compare the length of hospital stay between the two groups of patients.
NCT01226914 ↗	A Trial Comparing Wound Drainage and Post-operative Complications With and Without the Use of EVICEL™ Fibrin Sealant in Thyroidectomy	Completed	Medical University of South Carolina	N/A	2010-06-01	Primary Objectives - To compare the amount of post-operative wound drainage between the group of patients in which EVICEL™ spray is utilized (Arm A), and the group of patients in which an EVICEL™ placebo is utilized (Arm B). - To compare the length of time to drain removal between Arm A and Arm B. Secondary objectives - To compare the incident or rates of seroma, hematoma, and post-operative edema between the two groups. - To compare the reported pain experienced in each group at selected time points using a standard numerical rating scale (NRS). - To compare the length of hospital stay between the two groups of patients.
NCT01235715 ↗	The Use of Evicel to Reduce Blood Loss in Total Knee Replacement Surgery	Completed	Ethicon, Inc.	Phase 4	2010-09-01	Application of "Evicel" hemostatic matrix during operation for unilateral total knee replacement surgery (TKA) will result in decreased bleeding and postoperative drain output, a reduction in transfusion requirements, and less reduction of hemoglobin.

Clinical Trial Conditions for EVICEL FIBRIN SEALANT (HUMAN)

Condition Name

Condition Name for EVICEL FIBRIN SEALANT (HUMAN)
Intervention	Trials
Hereditary Hemorrhagic Telangiectasia (HHT)	2
Goiter	1
Osteoarthritis	1

Condition MeSH

Condition MeSH for EVICEL FIBRIN SEALANT (HUMAN)
Intervention	Trials
Telangiectasis	2
Telangiectasia, Hereditary Hemorrhagic	2
Epistaxis	2

Clinical Trial Locations for EVICEL FIBRIN SEALANT (HUMAN)

Trials by Country

Trials by Country for EVICEL FIBRIN SEALANT (HUMAN)
Location	Trials
United States	3
Italy	1

Trials by US State

Trials by US State for EVICEL FIBRIN SEALANT (HUMAN)
Location	Trials
California	2
New York	1

Clinical Trial Progress for EVICEL FIBRIN SEALANT (HUMAN)

Clinical Trial Phase

Clinical Trial Phase for EVICEL FIBRIN SEALANT (HUMAN)
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	1
Phase 2	2

Clinical Trial Status

Clinical Trial Status for EVICEL FIBRIN SEALANT (HUMAN)
Clinical Trial Phase	Trials
Completed	5
Withdrawn	1

Clinical Trial Sponsors for EVICEL FIBRIN SEALANT (HUMAN)

Sponsor Name

Sponsor Name for EVICEL FIBRIN SEALANT (HUMAN)
Sponsor	Trials
Ethicon, Inc.	2
University of California, San Diego	2
Medical University of South Carolina	1

Sponsor Type

Sponsor Type for EVICEL FIBRIN SEALANT (HUMAN)
Sponsor	Trials
Other	6
Industry	2